» Articles » PMID: 38895787

Time to Optimize Vaccination Strategies in Blood Cancer Patients

Overview
Journal Br J Haematol
Specialty Hematology
Date 2024 Jun 19
PMID 38895787
Authors
Affiliations
Soon will be listed here.
Abstract

Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS-CoV2 vaccine in patients with follicular lymphoma receiving front-line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points. Commentary on: Lim et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440-451.

Citing Articles

Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center.

Oliveira J, Cruz P, Dias T, Sousa-Pimenta M, Almeida B, Soares B Vaccines (Basel). 2024; 12(11).

PMID: 39591110 PMC: 11598862. DOI: 10.3390/vaccines12111207.